Haemonetics Corporation(HAE)Earnings, Financials & Key Ratios

HAE•NYSE

$52.64

$2.45B mkt cap·15.9× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Instruments Sub-IndustryDiagnostics and life science tools

AboutHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.Show more

Revenue$1.36B+4.0%
EBITDA$331M+30.5%
Net Income$168M+42.6%
EPS (Diluted)3.31+44.5%
Gross Margin57.21%+5.2%
EBITDA Margin24.3%+25.5%
Operating Margin16.3%+29.4%
Net Margin12.32%+37.2%
ROE18.83%+42.4%
ROIC10%+16.8%
Debt/Equity1.49+77.3%
Interest Coverage25.35+59.6%

Technical→

HAE Key Insights

Haemonetics Corporation (HAE) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong 5Y profit CAGR of 17.0%
✓Good 3Y average ROE of 15.6%

✗Weaknesses

✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

HAE Price & Volume

Haemonetics Corporation (HAE) stock price & volume — 10-year historical chart

Loading chart...

HAE Growth Metrics

Haemonetics Corporation (HAE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years4.1%

5 Years6.6%

3 Years11.07%

TTM-4.02%

Profit CAGR

10 Years25.8%

5 Years16.99%

3 Years56.94%

TTM34.88%

EPS CAGR

10 Years26.32%

5 Years17.47%

3 Years57.95%

TTM42.91%

Return on Capital

10 Years6.3%

5 Years8.7%

3 Years10.35%

Last Year11.77%

HAE Recent Earnings

Haemonetics Corporation (HAE) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)

Q1 2026Latest

Feb 5, 2026

EPS

$1.31

Est $1.27

+3.1%

Revenue

$339M

Est $332M

+2.1%

Q4 2025

Nov 6, 2025

EPS

$1.27

Est $1.12

+13.4%

Revenue

$327M

Est $330M

-0.7%

Q3 2025

Aug 7, 2025

EPS

$1.10

Est $1.01

+8.9%

Revenue

$321M

Est $320M

+0.4%

Q2 2025

May 8, 2025

EPS

$1.24

Est $1.22

+1.6%

Revenue

$331M

Est $312M

+5.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 5, 2026	$1.31vs $1.27+3.1%	$339Mvs $332M+2.1%
Q4 2025	Nov 6, 2025	$1.27vs $1.12+13.4%	$327Mvs $330M-0.7%
Q3 2025	Aug 7, 2025	$1.10vs $1.01+8.9%	$321Mvs $320M+0.4%
Q2 2025	May 8, 2025	$1.24vs $1.22+1.6%	$331Mvs $312M+5.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
TFXTeleflex IncorporatedDirect Competitor	5.45B	123.23	-6.09	-34.61%	-30.56%	-23.7%	0.87
HOLXHologic, Inc.Direct Competitor	16.97B	76.01	30.53	1.74%	13.18%	10.37%	0.52
ITGRInteger Holdings CorporationDirect Competitor	2.97B	86.29	29.86	7.57%	7.67%	8.23%	0.80
NVCRNovoCure LimitedDirect Competitor	1.88B	16.50	-13.52	8.28%	-25.66%	-50.82%	0.85
NNOXNano-X Imaging Ltd.Direct Competitor	117.04M	1.79	-1.97	13.91%	-452.82%	-35.55%	0.04
BAXBaxter International Inc.Product Competitor	8.77B	16.98	-9.70	5.72%	-9.7%	-16.5%	1.64
BDXBecton, Dickinson and CompanyProduct Competitor	52.45B	144.76	24.83	8.23%	8.01%	6.93%	0.76
ISRGIntuitive Surgical, Inc.Product Competitor	160.44B	451.73	57.40	20.51%	28.15%	16.89%	0.02

Compare HAE vs Peers

Haemonetics Corporation (HAE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TFX

Most directly comparable listed peer for HAE.

Scale Benchmark

vs ISRG

Larger-name benchmark to compare HAE against a more recognizable public peer.

Peer Set

Compare Top 5

vs TFX, HOLX, ITGR, NVCR

HAE Income Statement

Haemonetics Corporation (HAE) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Sales/Revenue	886.12M	903.92M	967.58M	988.48M	870.46M	993.2M	1.17B	1.31B	1.36B	1.32B
Revenue Growth %	-2.5%	2.01%	7.04%	2.16%	-11.94%	14.1%	17.67%	12.01%	3.95%	-4.02%
Cost of Goods Sold	507.62M	492.01M	550.04M	500.66M	442.02M	462.43M	545.79M	597.14M	582.28M	547.22M
COGS % of Revenue	57.29%	54.43%	56.85%	50.65%	50.78%	46.56%	46.7%	45.62%	42.79%	-
Gross Profit	378.49M▲ 0%	411.91M▲ 8.8%	417.54M▲ 1.4%	487.82M▲ 16.8%	428.45M▼ 12.2%	530.77M▲ 23.9%	622.87M▲ 17.4%	711.91M▲ 14.3%	778.55M▲ 9.4%	771.06M▲ 0%
Gross Margin %	42.71%	45.57%	43.15%	49.35%	49.22%	53.44%	53.3%	54.38%	57.21%	58.49%
Gross Profit Growth %	-6.76%	8.83%	1.37%	16.83%	-12.17%	23.88%	17.35%	14.3%	9.36%	-
Operating Expenses	397.88M	355.75M	333.99M	384.47M	338.7M	450.02M	466.84M	547.03M	556.73M	517.8M
OpEx % of Revenue	44.9%	39.36%	34.52%	38.9%	38.91%	45.31%	39.95%	41.79%	40.91%	-
Selling, General & Admin	301.73M	316.52M	298.28M	266.33M	263.83M	332.2M	373.95M	420.82M	422.05M	324.31M
SG&A % of Revenue	34.05%	35.02%	30.83%	26.94%	30.31%	33.45%	32%	32.15%	31.01%	-
Research & Development	47.26M	39.23M	35.71M	39.08M	40.66M	55.2M	58.63M	63.03M	69.42M	61.23M
R&D % of Revenue	5.33%	4.34%	3.69%	3.95%	4.67%	5.56%	5.02%	4.82%	5.1%	-
Other Operating Expenses	48.89M	0	0	79.05M	34.21M	62.62M	34.26M	63.18M	65.26M	1000K
Operating Income	-19.38M▲ 0%	56.16M▲ 389.8%	83.55M▲ 48.8%	103.35M▲ 23.7%	89.75M▼ 13.2%	80.75M▼ 10.0%	156.03M▲ 93.2%	164.88M▲ 5.7%	221.82M▲ 34.5%	253.26M▲ 0%
Operating Margin %	-2.19%	6.21%	8.63%	10.46%	10.31%	8.13%	13.35%	12.6%	16.3%	19.21%
Operating Income Growth %	55.89%	389.75%	48.77%	23.71%	-13.16%	-10.02%	93.23%	5.67%	34.53%	-
EBITDA	64.65M	145.4M	192.96M	195.54M	174.03M	167.3M	240.84M	253.5M	330.7M	365.86M
EBITDA Margin %	7.3%	16.09%	19.94%	19.78%	19.99%	16.84%	20.61%	19.36%	24.3%	27.75%
EBITDA Growth %	57.42%	124.9%	32.71%	1.34%	-11%	-3.87%	43.96%	5.26%	30.46%	27.55%
D&A (Non-Cash Add-back)	84.03M	89.25M	109.42M	92.19M	84.29M	86.55M	84.81M	88.61M	108.89M	112.61M
EBIT	39.21M	64.16M	83.55M	165.75M	100.1M	105.17M	167.2M	206.84M	247.1M	262.87M
Net Interest Income	-8.1M	-4.53M	-9.91M	-16.2M	-16.83M	-17.12M	-14.63M	-13.02M	-9.75M	-20M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	8.1M	4.53M	9.91M	16.2M	16.83M	17.12M	14.63M	13.02M	9.75M	20M
Other Income/Expense	-8.1M	3.48M	-9.91M	-16.2M	-16.83M	-17.12M	-14.63M	-13.02M	-9.75M	-26.09M
Pretax Income	-27.48M▲ 0%	59.63M▲ 317.0%	73.63M▲ 23.5%	87.15M▲ 18.4%	72.91M▼ 16.3%	63.63M▼ 12.7%	141.4M▲ 122.2%	151.87M▲ 7.4%	212.07M▲ 39.6%	227.17M▲ 0%
Pretax Margin %	-3.1%	6.6%	7.61%	8.82%	8.38%	6.41%	12.1%	11.6%	15.58%	17.23%
Income Tax	-1.21M	14.06M	18.61M	10.63M	-6.56M	20.25M	26M	34.31M	44.39M	51.73M
Effective Tax Rate %	4.4%	23.58%	25.28%	12.19%	-8.99%	31.83%	18.39%	22.59%	20.93%	22.77%
Net Income	-26.27M▲ 0%	45.57M▲ 273.5%	55.02M▲ 20.7%	76.53M▲ 39.1%	79.47M▲ 3.8%	43.38M▼ 45.4%	115.4M▲ 166.1%	117.56M▲ 1.9%	167.68M▲ 42.6%	175.44M▲ 0%
Net Margin %	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%	12.32%	13.31%
Net Income Growth %	52.77%	273.49%	20.73%	39.09%	3.85%	-45.42%	166.05%	1.87%	42.64%	34.88%
Net Income (Continuing)	-26.27M	45.57M	55.02M	76.53M	79.47M	43.38M	115.4M	117.56M	167.68M	175.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	-0.51▲ 0%	0.85▲ 266.7%	1.04▲ 22.4%	1.48▲ 42.3%	1.55▲ 4.7%	0.84▼ 45.8%	2.24▲ 166.7%	2.29▲ 2.2%	3.31▲ 44.5%	3.73▲ 0%
EPS Growth %	53.21%	266.67%	22.35%	42.31%	4.73%	-45.81%	166.67%	2.23%	44.54%	42.91%
EPS (Basic)	-0.51	0.86	1.07	1.51	1.57	0.85	2.27	2.32	3.31	-
Diluted Shares Outstanding	51.52M	53.5M	52.94M	51.81M	51.29M	51.35M	51.42M	51.4M	50.73M	46.99M
Basic Shares Outstanding	51.51M	52.76M	51.53M	50.69M	50.69M	51.05M	50.78M	50.71M	50.33M	46.79M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

HAE Balance Sheet

Haemonetics Corporation (HAE) balance sheet — assets, liabilities & shareholders' equity

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Total Current Assets	510.03M	521.18M	576.12M	603.64M	693.55M	756.03M	769.72M	768.9M	934.98M	943.67M
Cash & Short-Term Investments	139.56M	180.17M	169.35M	137.31M	192.31M	259.5M	284.47M	178.8M	306.76M	363.37M
Cash Only	139.56M	180.17M	169.35M	137.31M	192.31M	259.5M	284.47M	178.8M	306.76M	363.37M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	152.68M	151.23M	185.03M	165.21M	127.56M	159.38M	179.14M	206.56M	202.66M	195.71M
Days Sales Outstanding	62.89	61.06	69.8	61	53.49	58.57	55.95	57.6	54.36	55.8
Inventory	176.93M	160.8M	194.34M	270.28M	322.61M	293.03M	259.38M	317.2M	365.14M	321.19M
Days Inventory Outstanding	127.22	119.29	128.96	197.04	266.4	231.29	173.46	193.89	228.89	230.63
Other Current Assets	40.85M	28.98M	27.41M	0	0	0	46.73M	66.34M	60.41M	63.41M
Total Non-Current Assets	728.68M	716.16M	698.65M	663.47M	1.13B	1.1B	1.17B	1.43B	1.52B	1.55B
Property, Plant & Equipment	323.86M	332.16M	343.98M	253.4M	217.56M	258.48M	310.88M	366.63M	284.05M	297.23M
Fixed Asset Turnover	2.74x	2.72x	2.81x	3.90x	4.00x	3.84x	3.76x	3.57x	4.79x	4.54x
Goodwill	210.84M	211.4M	210.82M	210.65M	466.44M	467.29M	466.23M	565.08M	604.27M	606.83M
Intangible Assets	177.54M	156.59M	127.69M	133.11M	365.48M	310.26M	275.77M	406.12M	455.74M	419.73M
Long-Term Investments	-3.99M	-3.96M	-4.36M	0	0	0	0	0	0	12.9M
Other Non-Current Assets	16.44M	16.02M	16.16M	62.38M	70.88M	63.2M	106.97M	81.12M	164.11M	771.56M
Total Assets	1.24B▲ 0%	1.24B▼ 0.1%	1.27B▲ 3.0%	1.27B▼ 0.6%	1.82B▲ 43.6%	1.86B▲ 2.2%	1.93B▲ 4.0%	2.2B▲ 13.5%	2.45B▲ 11.6%	2.49B▲ 0%
Asset Turnover	0.72x	0.73x	0.76x	0.78x	0.48x	0.53x	0.60x	0.60x	0.56x	0.54x
Asset Growth %	-5.95%	-0.11%	3.02%	-0.6%	43.63%	2.19%	4.04%	13.48%	11.63%	3.64%
Total Current Liabilities	211.18M	384.7M	235.76M	274.82M	253.5M	442.27M	251.82M	300.38M	578.11M	539.87M
Accounts Payable	42.97M	55.27M	63.36M	50.73M	50.29M	58.37M	63.93M	73.36M	67M	48.69M
Days Payables Outstanding	30.9	41	42.05	36.98	41.53	46.07	42.75	44.84	42	37.25
Short-Term Debt	61.02M	194.26M	27.67M	76.98M	17.02M	214.15M	11.78M	10.23M	303.56M	304.75M
Deferred Revenue (Current)	26.48M	25.81M	27.28M	28.84M	26.27M	26.81M	30.21M	31.24M	43.35M	92.55M
Other Current Liabilities	32.76M	34.51M	55.8M	44.92M	80.95M	87.2M	81.42M	104.85M	104.78M	186.43M
Current Ratio	2.42x	1.35x	2.44x	2.20x	2.74x	1.71x	3.06x	2.56x	1.62x	1.62x
Quick Ratio	1.58x	0.94x	1.62x	1.21x	1.46x	1.05x	2.03x	1.50x	0.99x	0.99x
Cash Conversion Cycle	159.21	139.35	156.71	221.06	278.36	243.79	186.66	206.64	241.25	249.18
Total Non-Current Liabilities	287.92M	100.21M	371.14M	405.18M	834.76M	668.04M	865.01M	935.25M	1.05B	1.04B
Long-Term Debt	253.63M	59.42M	322.45M	305.51M	690.59M	559.44M	754.1M	797.56M	921.23M	919.99M
Capital Lease Obligations	0	0	0	52.01M	62.96M	0	0	0	0	0
Deferred Tax Liabilities	13.74M	9.38M	22.8M	14M	43.83M	28.73M	36.2M	62.64M	62.58M	236.24M
Other Non-Current Liabilities	22.18M	34.26M	25.89M	33.65M	37.38M	79.88M	74.72M	75.04M	68.19M	265.94M
Total Liabilities	499.1M	484.91M	606.9M	680M	1.09B	1.11B	1.12B	1.24B	1.63B	1.58B
Total Debt	314.65M	253.68M	350.12M	441.81M	778.28M	780.78M	765.89M	807.79M	1.22B	1.22B
Net Debt	175.08M	73.51M	180.77M	304.5M	585.97M	521.29M	481.42M	628.99M	918.02M	861.37M
Debt / Equity	0.43x	0.34x	0.52x	0.75x	1.06x	1.04x	0.94x	0.84x	1.49x	1.49x
Debt / EBITDA	4.87x	1.74x	1.81x	2.26x	4.47x	4.67x	3.18x	3.19x	3.70x	3.35x
Net Debt / EBITDA	2.71x	0.51x	0.94x	1.56x	3.37x	3.12x	2.00x	2.48x	2.78x	2.78x
Interest Coverage	4.84x	14.18x	8.43x	10.23x	5.95x	6.14x	11.43x	15.89x	25.35x	13.14x
Total Equity	739.61M▲ 0%	752.43M▲ 1.7%	667.87M▼ 11.2%	587.11M▼ 12.1%	731.67M▲ 24.6%	749.42M▲ 2.4%	818M▲ 9.2%	959.96M▲ 17.4%	820.84M▼ 14.5%	911.45M▲ 0%
Equity Growth %	2.73%	1.73%	-11.24%	-12.09%	24.62%	2.43%	9.15%	17.35%	-14.49%	-19.91%
Book Value per Share	14.35	14.06	12.62	11.33	14.26	14.59	15.91	18.68	16.18	19.40
Total Shareholders' Equity	739.61M	752.43M	667.87M	587.11M	731.67M	749.42M	818M	959.96M	820.84M	911.45M
Common Stock	523K	523K	510K	503K	509K	511K	504K	508K	482K	468K
Retained Earnings	289.92M	266.94M	161.42M	78.51M	157.98M	202.39M	253.17M	360.46M	352.17M	381.09M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-32.87M	-18.99M	-30.38M	-45.13M	-29.55M	-25.95M	-30.38M	-35.63M	-55.08M	-34.61M
Minority Interest	0	0	0	0	0	0	0	0	0	0

HAE Cash Flow Statement

Haemonetics Corporation (HAE) cash flow — operating, investing & free cash flow history

Line item	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Cash from Operations	159.74M	220.35M	159.28M	158.22M	108.81M	172.26M	273.06M	181.75M	181.72M	181.72M
Operating CF Margin %	18.03%	24.38%	16.46%	16.01%	12.5%	17.34%	23.37%	13.88%	13.35%	-
Operating CF Growth %	31.08%	37.94%	-27.71%	-0.67%	-31.23%	58.32%	58.51%	-33.44%	-0.01%	487.12%
Net Income	-26.27M	45.57M	55.02M	76.53M	79.47M	43.38M	115.4M	117.56M	167.68M	175.44M
Depreciation & Amortization	89.73M	89.25M	109.42M	110.29M	84.29M	97.75M	93.31M	97.22M	115.59M	112.61M
Stock-Based Compensation	9.15M	13.03M	17.19M	20.45M	25.52M	24.36M	25.58M	28.33M	29.64M	31.64M
Deferred Taxes	-6.8M	-5.83M	13.35M	-6.96M	-19.87M	5.01M	4.78M	-11.04M	-5.22M	-2.64M
Other Non-Cash Items	94.91M	1.85M	27.05M	42.47M	-919K	16.95M	8.48M	24.39M	-24M	-1.61M
Working Capital Changes	-983K	76.49M	-62.75M	-84.56M	-59.68M	-15.18M	25.5M	-74.7M	-101.96M	23.41M
Change in Receivables	3.15M	5.09M	-38.06M	18.86M	44.12M	-34.97M	-24.42M	-24.19M	6.96M	17.69M
Change in Inventory	-1.55M	14.38M	-39.32M	-84.72M	-38.91M	24.31M	30.75M	-60.06M	-64.7M	39.82M
Change in Payables	21.07M	41.4M	17.74M	-17.31M	0	0	39.82M	44.58M	0	-19.29M
Cash from Investing	-73.31M	-63.04M	-116.15M	-57.18M	-425.44M	-86.34M	-143.79M	-322.39M	-161.9M	-74.89M
Capital Expenditures	-76.14M	-74.8M	-118.96M	-48.76M	-37.04M	-96.51M	-110.19M	-66.3M	-39.28M	-30.76M
CapEx % of Revenue	8.59%	8.27%	12.29%	4.93%	4.26%	9.72%	9.43%	5.06%	2.89%	-
Acquisitions	2.82M	9M	2.81M	-25.19M	-390.22M	8.14M	-2M	-240.54M	-107.61M	45.74M
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	2.82M	2.76M	2.81M	16.77M	1.81M	2.02M	1.61M	0	-15M	-72.73M
Cash from Financing	-60.41M	-120.64M	-50.63M	-131.21M	367.45M	-15.75M	-100.36M	38.16M	108.82M	-228.41M
Debt Issued (Net)	-93.41M	-60.98M	95.93M	31.88M	418.13M	-17.5M	-9.63M	37.75M	447.31M	-706.25M
Equity Issued (Net)	33M	-100M	-160M	-175M	0	0	-75M	7.21M	-225M	482.91M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	-100M	-160M	-175M	0	0	-75M	0	-225M	-225M
Other Financing	0	40.34M	13.45M	11.92M	-50.67M	1.75M	-15.74M	-6.81M	-113.49M	-5.07M
Net Change in Cash	24.44M▲ 0%	40.6M▲ 66.1%	-10.82M▼ 126.6%	-32.04M▼ 196.2%	54.99M▲ 271.6%	67.19M▲ 22.2%	24.97M▼ 62.8%	-105.67M▼ 523.2%	127.96M▲ 221.1%	42.52M▲ 0%
Free Cash Flow	83.6M▲ 0%	145.55M▲ 74.1%	40.32M▼ 72.3%	109.46M▲ 171.5%	71.77M▼ 34.4%	75.75M▲ 5.6%	162.87M▲ 115.0%	115.45M▼ 29.1%	142.45M▲ 23.4%	308.07M▲ 0%
FCF Margin %	9.43%	16.1%	4.17%	11.07%	8.24%	7.63%	13.94%	8.82%	10.47%	23.37%
FCF Growth %	329.61%	74.1%	-72.3%	171.48%	-34.44%	5.56%	114.99%	-29.11%	23.38%	221.15%
FCF per Share	1.62	2.72	0.76	2.11	1.40	1.48	3.17	2.25	2.81	2.81
FCF Conversion (FCF/Net Income)	-6.08x	4.84x	2.90x	2.07x	1.37x	3.97x	2.37x	1.55x	1.08x	1.76x
Interest Paid	7.85M	7.66M	13.12M	12.54M	7.82M	6.19M	13.59M	0	16.53M	0
Taxes Paid	6.96M	9.08M	8.21M	11.51M	12.49M	24.3M	17.97M	0	49.29M	0

HAE Key Ratios

Haemonetics Corporation (HAE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	-3.6%	6.11%	7.75%	12.2%	12.05%	5.86%	14.72%	13.22%	18.83%	20.26%
Return on Invested Capital (ROIC)	-1.51%	4.84%	7.48%	8.91%	6.09%	4.68%	9.11%	8.56%	10%	10%
Gross Margin	42.71%	45.57%	43.15%	49.35%	49.22%	53.44%	53.3%	54.38%	57.21%	58.49%
Net Margin	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%	12.32%	13.31%
Debt / Equity	0.43x	0.34x	0.52x	0.75x	1.06x	1.04x	0.94x	0.84x	1.49x	1.49x
Interest Coverage	4.84x	14.18x	8.43x	10.23x	5.95x	6.14x	11.43x	15.89x	25.35x	13.14x
FCF Conversion	-6.08x	4.84x	2.90x	2.07x	1.37x	3.97x	2.37x	1.55x	1.08x	1.76x
Revenue Growth	-2.5%	2.01%	7.04%	2.16%	-11.94%	14.1%	17.67%	12.01%	3.95%	-4.02%

HAE SEC Filings & Documents

Haemonetics Corporation (HAE) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 1, 2026·SEC

Material company update

Mar 3, 2026·SEC

Material company update

Feb 12, 2026·SEC

10-K Annual Reports

FY 2025

May 21, 2025·SEC

FY 2024

May 20, 2024·SEC

FY 2023

May 22, 2023·SEC

10-Q Quarterly Reports

FY 2026

Feb 5, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

HAE Frequently Asked Questions

Haemonetics Corporation (HAE) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Haemonetics Corporation (HAE) reported $1.32B in revenue for fiscal year 2025. This represents a 374% increase from $278.2M in 1996.

Haemonetics Corporation (HAE) grew revenue by 4.0% over the past year. Growth has been modest.

Yes, Haemonetics Corporation (HAE) is profitable, generating $175.4M in net income for fiscal year 2025 (12.3% net margin).

Dividend & Returns

Haemonetics Corporation (HAE) has a return on equity (ROE) of 18.8%. This is reasonable for most industries.

Haemonetics Corporation (HAE) generated $308.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More HAE

Haemonetics Corporation (HAE) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Haemonetics Corporation(HAE)Earnings, Financials & Key Ratios

HAE Key Insights

✓Strengths

✗Weaknesses

HAE Price & Volume

HAE Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

HAE Recent Earnings

HAE Peer Comparison

Compare HAE vs Peers

vs TFX

vs ISRG

Compare Top 5

HAE Income Statement

HAE Balance Sheet

HAE Cash Flow Statement

HAE Key Ratios

HAE SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

HAE Frequently Asked Questions

Explore More HAE

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation